Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Oncology and Therapy

Open Access 01-09-2024 | Leukemia | Review

Causal Relationship Between Gut Microbiota and Leukemia: Future Perspectives

Authors: Qiang Yang, Zexin Wang, Miao Liu, Lingling Gan

Published in: Oncology and Therapy

Login to get access

Abstract

The gut microbiota plays a crucial role in maintaining homeostasis in the human gastrointestinal tract. Numerous studies have shown a strong association between the gut microbiota and the emergence and progression of various diseases. Leukemia is one of the most common hematologic malignancies. Although standardized protocols and expert consensus have been developed for routine diagnosis and treatment, limitations remain due to individual differences. Nevertheless, a large number of studies have established a link between the gut microbiota and leukemia, with disturbances in the gut microbiota directly or indirectly affecting the development of leukemia. However, the causal relationship between the two remains unclear, and studying and exploring the causal relationship may open up entirely new avenues and protocols for use in the prevention and/or treatment of leukemia, offering new insights into diagnosis and treatment. In this review, the intricate relationship between the gut microbiota and leukemia is explored in depth, including causal associations, metabolite effects, therapeutic applications, and complications. Based on the characteristics of the gut microbiota, the future applications and prospects of gut microbiota are discussed to provide useful information for clinical treatment of leukemia.
Literature
1.
Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J. 2013;2020(103):38–40.
2.
3.
4.
5.
Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18:719–31.PubMedPubMedCentralCrossRef
6.
7.
Kikushige Y. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. J Clin Exp Hematop JCEH. 2020;60:146–58.PubMedCrossRef
8.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97:1236–56.PubMedCrossRef
9.
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic myeloid leukemia, version 2. 2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2024;22:43–69.PubMedCrossRef
10.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.PubMedPubMedCentralCrossRef
11.
Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555:210–5.PubMedCrossRef
12.
Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev MMBR. 2017;81:e00036-e117.PubMedCrossRef
13.
14.
Cheng J, Ringel-Kulka T, Heikamp-de Jong I, Ringel Y, Carroll I, de Vos WM, et al. Discordant temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children. ISME J. 2016;10:1002–14.PubMedCrossRef
15.
Hollister EB, Riehle K, Luna RA, Weidler EM, Rubio-Gonzales M, Mistretta T-A, et al. Structure and function of the healthy pre-adolescent pediatric gut microbiome. Microbiome. 2015;3:36.PubMedPubMedCentralCrossRef
16.
17.
Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904.PubMedCrossRef
18.
19.
Zapata HJ, Quagliarello VJ. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc. 2015;63:776–81.PubMedPubMedCentralCrossRef
20.
Maeda Y, Takeda K. Host-microbiota interactions in rheumatoid arthritis. Exp Mol Med. 2019;51:1–6.PubMedCrossRef
21.
Kaur G, Behl T, Bungau S, Kumar A, Uddin MS, Mehta V, et al. Dysregulation of the gut-brain axis, dysbiosis and influence of numerous factors on gut microbiota associated Parkinson’s disease. Curr Neuropharmacol. 2021;19:233–47.PubMedPubMedCentralCrossRef
22.
23.
24.
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65.PubMedPubMedCentralCrossRef
25.
Mandal RS, Saha S, Das S. Metagenomic surveys of gut microbiota. Genom Proteom Bioinform. 2015;13:148–58.CrossRef
26.
Riley DR, Sieber KB, Robinson KM, White JR, Ganesan A, Nourbakhsh S, et al. Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples. PLoS Comput Biol. 2013;9: e1003107.PubMedPubMedCentralCrossRef
27.
Allegra A, Innao V, Allegra AG, Ettari R, Pugliese M, Pulvirenti N, et al. Role of the microbiota in hematologic malignancies. Neth J Med. 2019;77:67–80.PubMed
28.
Guevara-Ramírez P, Cadena-Ullauri S, Paz-Cruz E, Tamayo-Trujillo R, Ruiz-Pozo VA, Zambrano AK. Role of the gut microbiota in hematologic cancer. Front Microbiol. 2023;14:1185787.PubMedPubMedCentralCrossRef
29.
de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71:1020–32.PubMedCrossRef
30.
Nakkarach A, Foo HL, Song AA-L, Mutalib NEA, Nitisinprasert S, Withayagiat U. Anti-cancer and anti-inflammatory effects elicited by short chain fatty acids produced by Escherichia coli isolated from healthy human gut microbiota. Microb Cell Fact. 2021;20:36.PubMedPubMedCentralCrossRef
31.
Cheng WY, Wu C-Y, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut. 2020;69:1867–76.PubMedCrossRef
32.
Thomas R, Wong WSW, Saadon R, Vilboux T, Deeken J, Niederhuber J, et al. Gut microbial composition difference between pediatric ALL survivors and siblings. Pediatr Hematol Oncol. 2020;37:475–88.PubMedPubMedCentralCrossRef
33.
De Pietri S, Ingham AC, Frandsen TL, Rathe M, Krych L, Castro-Mejía JL, et al. Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota. Int J Cancer. 2020;147:1953–62.PubMedCrossRef
34.
35.
Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, et al. Gut microbiome composition predicts infection risk during chemotherapy in children with acute lymphoblastic leukemia. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67:541–8.CrossRef
36.
Vicente-Dueñas C, Janssen S, Oldenburg M, Auer F, González-Herrero I, Casado-García A, et al. An intact gut microbiome protects genetically predisposed mice against leukemia. Blood. 2020;136:2003–17.PubMedPubMedCentralCrossRef
37.
Marcotte EL, Richardson MR, Roesler MA, Spector LG. Cesarean delivery and risk of infant leukemia: a report from the Children’s Oncology Group. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2018;27:473–8.CrossRef
38.
Masetti R, Muratore E, Leardini D, Zama D, Turroni S, Brigidi P, et al. Gut microbiome in pediatric acute leukemia: from predisposition to cure. Blood Adv. 2021;5:4619–29.PubMedPubMedCentralCrossRef
39.
Li H, Sun B, Ning X, Jiang S, Sun L. A comparative analysis of Edwardsiella tarda-induced transcriptome profiles in RAW264.7 cells reveals new insights into the strategy of bacterial immune evasion. Int J Mol Sci. 2019;20:5724.PubMedPubMedCentralCrossRef
40.
Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–15.PubMedPubMedCentralCrossRef
41.
Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167:1897.PubMedCrossRef
42.
Faitová T, Svanberg R, Da Cunha-Bang C, Ilett EE, Jørgensen M, Noguera-Julian M, et al. The gut microbiome in patients with chronic lymphocytic leukemia. Haematologica. 2022;107:2238–43.PubMedPubMedCentralCrossRef
43.
44.
Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, et al. Gut microbiome signatures are predictive of infectious risk following induction therapy for acute myeloid leukemia. Clin Infect Dis. 2020;71:63–71.PubMedCrossRef
45.
Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, et al. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016;122:2186–96.PubMedCrossRef
46.
Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Halaweish HF, Kaiser T, et al. Lasting shift in the gut microbiota in patients with acute myeloid leukemia. Blood Adv. 2022;6:3451–7.PubMedPubMedCentralCrossRef
47.
Pötgens SA, Lecop S, Havelange V, Li F, Neyrinck AM, Neveux N, et al. Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss. Clin Nutr. 2023;42:2214–28.PubMedCrossRef
48.
49.
van den Bogert B, Erkus O, Boekhorst J, de Goffau M, Smid EJ, Zoetendal EG, et al. Diversity of human small intestinal Streptococcus and Veillonella populations. FEMS Microbiol Ecol. 2013;85:376–88.PubMedCrossRef
50.
51.
Almuhayawi MS, Mohamed MSM, Abdel-Mawgoud M, Selim S, Al Jaouni SK, AbdElgawad H. Bioactive potential of several actinobacteria isolated from microbiologically barely explored desert habitat. Saudi Arab Biol. 2021;10:235.
52.
53.
Long Y, Tang L, Zhou Y, Zhao S, Zhu H. Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study. BMC Med. 2023;21:66.PubMedPubMedCentralCrossRef
54.
Liu X, Chen Y, Zhang S, Dong L. Gut microbiota-mediated immunomodulation in tumor. J Exp Clin Cancer Res CR. 2021;40:221.PubMedCrossRef
55.
Qu R, Zhang Y, Ma Y, Zhou X, Sun L, Jiang C, et al. Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer. Adv Sci Weinh Baden-Wurtt Ger. 2023;10: e2205563.
56.
57.
Zhao Y, Liu Y, Li S, Peng Z, Liu X, Chen J, et al. Role of lung and gut microbiota on lung cancer pathogenesis. J Cancer Res Clin Oncol. 2021;147:2177–86.PubMedPubMedCentralCrossRef
58.
59.
Luqman A, Hassan A, Ullah M, Naseem S, Ullah M, Zhang L, et al. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder. Front Immunol. 2024;15:1321395.PubMedPubMedCentralCrossRef
60.
Hemmati M, Kashanipoor S, Mazaheri P, Alibabaei F, Babaeizad A, Asli S, et al. Importance of gut microbiota metabolites in the development of cardiovascular diseases (CVD). Life Sci. 2023;329: 121947.PubMedCrossRef
61.
Zhang L, Chu J, Hao W, Zhang J, Li H, Yang C, et al. Gut microbiota and type 2 diabetes mellitus: association, mechanism, and translational applications. Mediat Inflamm. 2021;2021:5110276.CrossRef
62.
Mantziaris V, Kolios G. Gut microbiota, atherosclerosis, and therapeutic targets. Crit Pathw Cardiol. 2019;18:139–42.PubMedCrossRef
63.
64.
65.
Yang Z, Wang Q, Liu Y, Wang L, Ge Z, Li Z, et al. Gut microbiota and hypertension: association, mechanisms and treatment. Clin Exp Hypertens N Y N. 1993;2023(45):2195135.
66.
67.
Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, et al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. 2000;66:1654–61.PubMedPubMedCentralCrossRef
68.
Portincasa P, Bonfrate L, Vacca M, De Angelis M, Farella I, Lanza E, et al. Gut microbiota and short chain fatty acids: implications in glucose homeostasis. Int J Mol Sci. 2022;23:1105.PubMedPubMedCentralCrossRef
69.
Zhang L, Liu C, Jiang Q, Yin Y. Butyrate in energy metabolism: there is still more to learn. Trends Endocrinol Metab. 2021;32:159–69.PubMedCrossRef
70.
Wang R, Yang X, Liu J, Zhong F, Zhang C, Chen Y, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. Nat Commun. 2022;13:2522.PubMedPubMedCentralCrossRef
71.
Ghrewati M, Manji F, Modi V, Chandran C, Maroules M. Severe metabolic acidemia in a patient with aleukemic leukemia. Case Rep Nephrol. 2018;2018:1019034.PubMedPubMedCentral
72.
Gökçe M, Unal S, Gülşen H, Başaran O, Cetin M, Gümrük F, et al. A rare metabolic complication of acute lymphoblastic leukemia in childhood: lactic acidosis. Turk J Pediatr. 2012;54:61–3.PubMed
73.
Sayyed AH, Aleem A, Al-Katari MS, Algahtani F, Aljerian K, Aleem TA, et al. Acute lymphoblastic leukemia presenting with liver infiltration and severe lactic acidosis. Am J Case Rep. 2018;19:453–7.PubMedPubMedCentralCrossRef
74.
75.
Eslami M, Sadrifar S, Karbalaei M, Keikha M, Kobyliak NM, Yousefi B. Importance of the microbiota inhibitory mechanism on the Warburg effect in colorectal cancer cells. J Gastrointest Cancer. 2020;51:738–47.PubMedCrossRef
76.
Lundø K, Trauelsen M, Pedersen SF, Schwartz TW. Why Warburg works: lactate controls immune evasion through GPR81. Cell Metab. 2020;31:666–8.PubMedCrossRef
77.
Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206: 107451.PubMedCrossRef
78.
Noonan KL, Ho C, Laskin J, Murray N. The influence of the evolution of first-line chemotherapy on steadily improving survival in advanced non-small-cell lung cancer clinical trials. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10:1523–31.
79.
Lucafò M, Franzin M, Lagatolla C, Franca R, Bramuzzo M, Stocco G, et al. Emerging insights on the interaction between anticancer and immunosuppressant drugs and intestinal microbiota in pediatric patients. Clin Transl Sci. 2020;13:238–59.PubMedCrossRef
80.
Ben-Lulu S, Pollak Y, Mogilner J, Bejar J, Coran GA, Sukhotnik I. Dietary transforming growth factor-beta 2 (TGF-β2) supplementation reduces methotrexate-induced intestinal mucosal injury in a rat. PloS One. 2012;7:e45221.PubMedPubMedCentralCrossRef
81.
Kolli VK, Abraham P, Isaac B, Kasthuri N. Preclinical efficacy of melatonin to reduce methotrexate-induced oxidative stress and small intestinal damage in rats. Dig Dis Sci. 2013;58:959–69.PubMedCrossRef
82.
Zhou B, Xia X, Wang P, Chen S, Yu C, Huang R, et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. EBioMedicine. 2018;33:122–33.PubMedPubMedCentralCrossRef
83.
Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–6.PubMedPubMedCentralCrossRef
84.
Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, et al. Children’s Oncology Group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022;40:2106–18.PubMedPubMedCentralCrossRef
85.
Zhu Y, Jian X, Chen S, An G, Jiang D, Yang Q, et al. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma. Cell Metab. 2024;36:159-175.e8.PubMedCrossRef
86.
87.
Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68:321–31.PubMedCrossRef
88.
Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91:1076–81.PubMedCrossRef
89.
Escrihuela-Vidal F, Laporte J, Albasanz-Puig A, Gudiol C. Update on the management of febrile neutropenia in hematologic patients. Rev Esp Quimioter. 2019;32:55–8.PubMedPubMedCentral
90.
Rattanathammethee T, Tuitemwong P, Thiennimitr P, Sarichai P, Na Pombejra S, Piriyakhuntorn P, et al. Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy. PLoS ONE. 2020;15: e0236460.PubMedPubMedCentralCrossRef
91.
Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Nalluri H, Kaiser T, et al. Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome. 2021;9:211.PubMedPubMedCentralCrossRef
92.
Gyssens IC, Kern WV, Livermore DM. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–5.PubMedPubMedCentralCrossRef
93.
Shen Z, Gu X, Cao H, Mao W, Yang L, He M, et al. Characterization of microbiota in acute leukemia patients following successful remission induction chemotherapy without antimicrobial prophylaxis. Int Microbiol Off J Span Soc Microbiol. 2021;24:263–73.
94.
Rashidi A, Kaiser T, Shields-Cutler R, Graiziger C, Holtan SG, Rehman TU, et al. Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia. Sci Rep. 2019;9:6083.PubMedPubMedCentralCrossRef
95.
Laoprasopwattana K, Khwanna T, Suwankeeree P, Sujjanunt T, Tunyapanit W, Chelae S. Ciprofloxacin reduces occurrence of fever in children with acute leukemia who develop neutropenia during chemotherapy. Pediatr Infect Dis J. 2013;32:e94-98.PubMedCrossRef
96.
Chen S-M, Liu S-X, Chen F, Wang C-Y, Mai H-R, Yuan X-L, et al. Changes of intestinal flora in children with acute lymphoblastic leukemia before and after chemotherapy. Zhongguo Dang Dai Er Ke Za Zhi Chin J Contemp Pediatr. 2022;24:550–60.
97.
Liu X, Zou Y, Zhang Y, Liu L, Duan Y, Zhang A, et al. Characteristics in gut microbiome is associated with chemotherapy-induced pneumonia in pediatric acute lymphoblastic leukemia. BMC Cancer. 2021;21:1190.PubMedPubMedCentralCrossRef
98.
99.
Liu J, Luo W, Chen Q, Chen X, Zhou G, Sun H. Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota. Cancer Chemother Pharmacol. 2022;89:243–53.PubMedPubMedCentralCrossRef
100.
Resino E, San-Juan R, Aguado JM. Selective intestinal decontamination for the prevention of early bacterial infections after liver transplantation. World J Gastroenterol. 2016;22:5950–7.PubMedPubMedCentralCrossRef
101.
Wiesner RH, Hermans PE, Rakela J, Washington JA, Perkins JD, DiCecco S, et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation. 1988;45:570–4.PubMedCrossRef
102.
Kronman MP, Zerr DM, Qin X, Englund J, Cornell C, Sanders JE, et al. Intestinal decontamination of multidrug-resistant Klebsiella pneumoniae after recurrent infections in an immunocompromised host. Diagn Microbiol Infect Dis. 2014;80:87–9.PubMedPubMedCentralCrossRef
103.
Barsuk AL, Nekaeva ES, Lovtsova LV, Urakov AL. Selective intestinal decontamination as a method for preventing infectious complications (Review). Mod Technol Med. 2020;12:86–95.
104.
Buelow E, Gonzalez TB, Versluis D, Oostdijk EAN, Ogilvie LA, van Mourik MSM, et al. Effects of selective digestive decontamination (SDD) on the gut resistome. J Antimicrob Chemother. 2014;69:2215–23.PubMedCrossRef
105.
106.
Webb BJ, Brunner A, Ford CD, Gazdik MA, Petersen FB, Hoda D. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis Off J Transplant Soc. 2016;18:628–33.CrossRef
107.
108.
109.
110.
Hong T, Wang R, Wang X, Yang S, Wang W, Gao Q, et al. Interplay between the intestinal microbiota and acute graft-versus-host disease: experimental evidence and clinical significance. Front Immunol. 2021;12: 644982.PubMedPubMedCentralCrossRef
111.
Li J, Zhang X, Chen Y, Zheng Q, Zhao M, Jiang H. A promising insight: the potential influence and therapeutic value of the gut microbiota in GI GVHD. Oxid Med Cell Longev. 2022;2022:2124627.PubMedPubMedCentral
112.
Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Kazadi D, Halaweish H, et al. Potential of fecal microbiota transplantation to prevent acute graft-versus-host disease: analysis from a phase 2 trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29:4920–9.CrossRef
113.
Sofi MH, Wu Y, Ticer T, Schutt S, Bastian D, Choi H-J, et al. A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD. JCI Insight. 2021;6:e136841.PubMedPubMedCentralCrossRef
114.
Taur Y, Jenq RR, Perales M-A, Littmann ER, Morjaria S, Ling L, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124:1174–82.PubMedPubMedCentralCrossRef
115.
Ugrayová S, Švec P, Hric I, Šardzíková S, Kubáňová L, Penesová A, et al. Gut microbiome suffers from hematopoietic stem cell transplantation in childhood and its characteristics are positively associated with intra-hospital physical exercise. Biology. 2022;11:785.PubMedPubMedCentralCrossRef
116.
Zhang L, Xiang Y, Li Y, Zhang J. Gut microbiome in multiple myeloma: mechanisms of progression and clinical applications. Front Immunol. 2022;13:1058272.PubMedPubMedCentralCrossRef
117.
Kusakabe S, Fukushima K, Maeda T, Motooka D, Nakamura S, Fujita J, et al. Pre- and post-serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation. Br J Haematol. 2020;188:438–49.PubMedCrossRef
118.
D’Angelo C, Sudakaran S, Asimakopoulos F, Hematti P, El-Gamal D, Safdar N, et al. Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma. Leuk Lymphoma. 2023;64:87–97.PubMedCrossRef
119.
Khan N, Lindner S, Gomes ALC, Devlin SM, Shah GL, Sung AD, et al. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood. 2021;137:1527–37.PubMedPubMedCentralCrossRef
120.
Ren G, Zhang J, Li M, Tang Z, Yang Z, Cheng G, et al. Gut microbiota composition influences outcomes of skeletal muscle nutritional intervention via blended protein supplementation in posttransplant patients with hematological malignancies. Clin Nutr Edinb Scotl. 2021;40:94–102.
121.
Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun. 2022;13:5313.PubMedPubMedCentralCrossRef
122.
Xia T, Zhang B, Li Y, Fang B, Zhu X, Xu B, et al. New insight into 20(S)-ginsenoside Rh2 against T-cell acute lymphoblastic leukemia associated with the gut microbiota and the immune system. Eur J Med Chem. 2020;203: 112582.PubMedCrossRef
123.
Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.PubMedPubMedCentralCrossRef
124.
Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360:eaan5931.PubMedPubMedCentralCrossRef
125.
Vindigni SM, Surawicz CM. Fecal microbiota transplantation. Gastroenterol Clin North Am. 2017;46:171–85.PubMedCrossRef
126.
Wang J-W, Kuo C-H, Kuo F-C, Wang Y-K, Hsu W-H, Yu F-J, et al. Fecal microbiota transplantation: review and update. J Formos Med Assoc Taiwan Yi Zhi. 2019;118(Suppl 1):S23-31.PubMedCrossRef
127.
Tkach S, Dorofeyev A, Kuzenko I, Boyko N, Falalyeyeva T, Boccuto L, et al. Current status and future therapeutic options for fecal microbiota transplantation. Med Kaunas Lith. 2022;58:84.
128.
van Lier YF, Davids M, Haverkate NJE, de Groot PF, Donker ML, Meijer E, et al. Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. Sci Transl Med. 2020;12:eaaz8926.PubMedCrossRef
129.
Zhao Y, Li X, Zhou Y, Gao J, Jiao Y, Zhu B, et al. Safety and efficacy of fecal microbiota transplantation for grade IV steroid refractory GI-GvHD patients: interim results from FMT2017002 trial. Front Immunol. 2021;12: 678476.PubMedPubMedCentralCrossRef
130.
Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174:1406-1423.e16.PubMedCrossRef
131.
Wang Q, Fu YW, Wang YQ, Ai H, Yuan FF, Wei XD, et al. Fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi. 2019;40:853–5.PubMed
132.
Malard F, Vekhoff A, Lapusan S, Isnard F, Dincan-Corda E, Rey J, et al. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun. 2021;12:3084.PubMedPubMedCentralCrossRef
133.
DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018;2:745–53.PubMedPubMedCentralCrossRef
134.
Taur Y, Coyte K, Schluter J, Robilotti E, Figueroa C, Gjonbalaj M, et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018;10:p9489.CrossRef
135.
Kuai X-Y, Yao X-H, Xu L-J, Zhou Y-Q, Zhang L-P, Liu Y, et al. Evaluation of fecal microbiota transplantation in Parkinson’s disease patients with constipation. Microb Cell Factories. 2021;20:98.CrossRef
136.
Reyna-Figueroa J, Barrón-Calvillo E, García-Parra C, Galindo-Delgado P, Contreras-Ochoa C, Lagunas-Martínez A, et al. Probiotic supplementation decreases chemotherapy-induced gastrointestinal side effects in patients with acute leukemia. J Pediatr Hematol Oncol. 2019;41:468–72.PubMedCrossRef
137.
Redman MG, Ward EJ, Phillips RS. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25:1919–29.PubMedCrossRef
138.
Wardill HR, Van Sebille YZA, Ciorba MA, Bowen JM. Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. Curr Opin Support Palliat Care. 2018;12:187–97.PubMedCrossRef
139.
Wu X, Hou Q, Zhao Z, Wang J, Guo Y, Lu L, et al. Effects of soy-whey protein nutritional supplementation on hematopoiesis and immune reconstitution in an allogeneic transplanted mice. Nutrients. 2022;14:3014.PubMedPubMedCentralCrossRef
140.
Zhou R, He D, Xie J, Zhou Q, Zeng H, Li H, et al. The synergistic effects of polysaccharides and ginsenosides from American Ginseng (Panax quinquefolius L.) ameliorating cyclophosphamide-induced intestinal immune disorders and gut barrier dysfunctions based on microbiome-metabolomics analysis. Front Immunol. 2021;12:665901.PubMedPubMedCentralCrossRef
141.
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–8.PubMedPubMedCentralCrossRef
142.
Rajagopala SV, Yooseph S, Harkins DM, Moncera KJ, Zabokrtsky KB, Torralba MG, et al. Gastrointestinal microbial populations can distinguish pediatric and adolescent acute lymphoblastic leukemia (ALL) at the time of disease diagnosis. BMC Genom. 2016;17:635.CrossRef
143.
Rajagopala SV, Singh H, Yu Y, Zabokrtsky KB, Torralba MG, Moncera KJ, et al. Persistent gut microbial dysbiosis in children with acute lymphoblastic leukemia (ALL) during chemotherapy. Microb Ecol. 2020;79:1034–43.PubMedCrossRef
144.
Gao X, Miao R, Zhu Y, Lin C, Yang X, Jia R, et al. A new insight into acute lymphoblastic leukemia in children: influences of changed intestinal microfloras. BMC Pediatr. 2020;20:290.PubMedPubMedCentralCrossRef
145.
Chua LL, Rajasuriar R, Lim YAL, Woo YL, Loke P, Ariffin H. Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy. BMC Cancer. 2020;20:151.PubMedPubMedCentralCrossRef
146.
Liu X, Zou Y, Ruan M, Chang L, Chen X, Wang S, et al. Pediatric acute lymphoblastic leukemia patients exhibit distinctive alterations in the gut microbiota. Front Cell Infect Microbiol. 2020;10: 558799.PubMedPubMedCentralCrossRef
147.
Bhuta R, DeNardo B, Wang J, Atoyan J, Zhang Y, Nelson D, et al. Durable changes in the gut microbiome in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68: e29308.PubMedCrossRef
Metadata
Title
Causal Relationship Between Gut Microbiota and Leukemia: Future Perspectives
Authors
Qiang Yang
Zexin Wang
Miao Liu
Lingling Gan
Publication date
01-09-2024
Publisher
Springer Healthcare
Published in
Oncology and Therapy
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-024-00300-8

2024 ESMO Congress

Add-on Ra223 could be a new first-line option in mCRPC

Adding radium-223 to first-line enzalutamide significantly improves the survival of patients with bone metastatic castration-resistant prostate cancer.

Read more

AI model can predict tumor mutations

No OS benefit of adding preoperative CRT in gastric cancer

T-DXd supported for breast cancer with brain metastases

» View more highlights on the ESMO 2024 hub page

SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

  • Webinar | 01-10-2024 | 12:30 (CEST)

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Get a reminder for the on-demand version
Image Credits